Clinical aspects of Helicobacter pylori infection

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 7-8, 2008, Pages 426-430

  Bartnik, Witold ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Antibacterial treatment; Clarithromycin; Eradication; Gastric cancer; Helicobacter pylori; Metronidazole; Peptic ulcer

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BISMUTH CITRATE; BISMUTH SALT; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC SENSITIVITY; ATROPHIC GASTRITIS; BREATH ANALYSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION CONTROL; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PEPTIC ULCER; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SEROLOGY; STOMACH CANCER; SYMPTOMATOLOGY; TREATMENT FAILURE;

EID: 49249087430     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.440     Document Type: Review

References (30)

1. Linz B, Balloux F, Moodley Y, et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature. 2007; 445: 915-918.
2. Rowland M, Daly L, Vaughan M, et al. Age-specific incidence of Helicobacter pylori. Gastroenterology. 2006; 130: 65-72.
3. Naylor GM, Gotoda T, Nixon M, et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut. 2006; 56: 1545-1552.
4. Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology. 2008; 134: 306-323.
5. Łaszewicz W. Wyniki badań nad zakażeniem Helicobacter pylori. Białystok, Trans Humana - Wydawnictwo Uniwersyteckie, 2004.
6. Kim JS, Chung SJ, Choi YS, et al. Helicobacter pylori eradication for low-grade gastric mucosa-associated lymphoid tissue lymphoma is more successful in inducing remission in distal compared to proximal disease. Br J Cancer. 2007; 96: 1324-1328.
7. Tack J, Hallsy NJ, Camilieri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006; 130: 1466-1479.
8. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007; 56: 772-781.
9. Ernest PB, Peura DA, Crowe SE. Translation of Helicobacter pylori basic research to patient care. Gastroenterology. 2006; 130: 188-206.
10. Wojciechowska U, Didkowska J, Tarkowski W, et al. Nowotwory zlośliwe w Polsce w 2004 roku. Warszawa, Wydawnictwo Centrum Onkologii, 2006.
11. Correa P, Houghton J-M. Carcinogenesis of Helicobacter pylori. Gastroenterology. 2007; 133: 659-672.
12. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst. 2000; 92: 1881-1888.
13. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut. 2004; 53: 1244-1249.
14. Fuccio L, Zagari RM, Minardi ME, et al. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther. 2007; 25: 133-141.
15. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004; 291: 187-194.
16. Dzierzanowska-Fangrat K, Rożynek E, Celińska-Cedro D, et al. Antimicrobial resistance of Helicobacter pylori in Poland: a multicenter study. Int J Antimicrob Agents. 2005; 26: 230-234.
17. Dzieniszewski J, Jarosz M; Grupa Robocza PTG. Postȩpowanie w zakażeniu Helicobacter pylori (rok 2004). Wytyczne opracowane przez Grupȩ Robocza̧. Polskiego Towarzystwa Gastroenterologii. Gastroenterol Pol. 2004; 11: 41-48.
18. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; 53: 1374-1384.
19. Megraud F. Update on therapeutic options for Helicobacter pylori-related diseases. Curr Infect Dis Rep. 2005; 7: 115-120.
20. Perri F, Villani MR, Quitadamo M, et al. Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? Aliment Pharmacol Ther. 2001; 15: 1017-1022.
21. Calvet X, Ducons J, Bujanda L, et al. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol. 2005; 100: 1696-1701.
22. Zullo A, De Francisco V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007; 56: 1353-1357.
23. Francavilla R, Lionetti E, Castellaneta SP, et al. Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology. 2005; 129: 1414-1419.
24. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication. Ann Intern Med. 2007; 146: 556-563.
25. Di Mario F, Cavallaro LG, Scarpignato C. 'Rescue' therapies for the management of Helicobacter pylori infection. Dig Dis. 2006; 24: 113-130.
26. Nista EC, Candelli M, Zocco M, et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol. 2006; 101: 1985-1990.
27. Czerwionka-Szaflarska M, Murawska S. Rola probiotyków w leczeniu eradykacyjnym Helicobacter pylori. Przegl Gastroenterol. 2006; 1: 121-125.
28. Tong JL, Ran ZH, Shen J, et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007; 25: 155-168.
29. Niv Y, Hazazi R. Helicobacter pylori recurrence in developed and developing countries: meta-analysis of 13C-urea breath test follow-up after eradication. Helicobacter. 2008; 13: 56-61.
30. Sheu B-S, Cheng H-C, Yang Y-J, et al. The presence of dental disease can be a risk factor for recurrent Helicobacter pylori infection after eradication therapy: A 3-year follow-up. Endoscopy. 2007; 39: 942-947.